Ana Sayfa Biyoteknoloji Fresenius Submits Application to EMA for Adalimumab Biosimilar

Fresenius Submits Application to EMA for Adalimumab Biosimilar

The headquarters of Fresenius is pictured in Bad Homburg near Frankfurt February 24, 2010. REUTERS/Johannes Eisele

Fresenius SE & Co. KGaA (FRE.XE) said Monday that it has submitted a biosimilar marketing authorization application to the European Medicines Agency for adalimumab.

Fresenius’s drug is a biosimilar candidate of AbbVie Inc.’s (ABBV) Humira, which is used to treat chronic inflammatory autoimmune conditions such as arthritis and Crohn’s disease.

Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com

(END) Dow Jones Newswires